Physician profile
Dina Krupnik
NPI 1972985976
$2,024.26
in general payments reported to CMS, 2019-2025
15 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $385 · 2022: $587 · 2023: $364 · 2024: $252 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $467.36 | 2021-2023 | Pressurewire, Xience Skypoint, Dragonfly Opstar |
| Horizon Therapeutics Plc | $305.57 | 2021-2022 | |
| Abbvie INC. | $302.02 | 2021-2025 | |
| Lilly USA, LLC | $285.49 | 2021-2024 | Mounjaro |
| Axsome Therapeutics, INC. | $205.36 | 2025 | Symbravo |
| Novo Nordisk INC | $169.39 | 2022-2025 | Ozempic, Rybelsus |
| Cardiovascular Systems INC. | $64.36 | 2022-2023 | Diamondback Peripheral |
| Shockwave Medical, INC | $47.09 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $44.04 | 2021 | |
| Edwards Lifesciences Corporation | $28.57 | 2024 | Sapien 3 Ultra Resilia |
| Angiodynamics, INC. | $25.81 | 2025 | Solero |
| Glaxosmithkline, LLC. | $22.14 | 2022 | |
| Biosense Webster, INC. | $21.77 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.04 | 2023 | Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Krupnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.